Home › Therapeutic areas › Dermatology › Psoriasis
Psoriasis (8 companies)
Companies with an active program in Psoriasis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AARD | Aardvark Therapeutics | DermatologyMetabolic+1 Rare | 1 | Phase 3 | $25.2M | 3 |
| ALMS | Alumis | DermatologyImmunology+1 | 1 | Phase 3 | $628M | 5 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 1 | Approved | $1.36B | 9 |
| ORKA | Oruka Therapeutics | DermatologyImmunology Rare | 3 | Phase 2 | $6.53B | 7 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 2 | Approved | $8.14B | 12 |
| RVPH | Reviva Pharmaceuticals | CardiovascularDermatology+3 Rare | 1 | Phase 3 | $4.7M | 11 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 2 | Approved | $230M | 27 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 1 | NDA Submitted | $1.88B | 11 |
No companies match.